A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
References herein to “we,” “us,” “our,” the “Company,” and “Penumbra,” refer to Penumbra, Inc. and its consolidated subsidiaries unless expressly indicated or the context requires otherwise. Penumbra, the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety, and simplicity. Our team focuses on developing, manufacturing and marketing novel products for use by specialist physicians and other healthcare providers to drive improved clinical and health outcomes. We believe that the cost-effectiveness of our products is attractive to our customers.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.4B | 1.4B | 1.2B | 1.1B | 847M | 748M |
| Net Income | 178M | 178M | 14M | 91M | -2.0M | 5.3M |
| EPS | $4.52 | $4.52 | $0.36 | $2.32 | $-0.05 | $0.14 |
| Free Cash Flow | 175M | 175M | 147M | 82M | -75M | -12M |
| ROIC | 11.2% | 16.9% | 0.7% | 8.4% | 0.5% | 0.6% |
| Gross Margin | 67.1% | 67.1% | 63.2% | 64.5% | 63.2% | 63.6% |
| Debt/Equity | 0.15 | 0.15 | 0.02 | 0.02 | 0.03 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 189M | 189M | 9.3M | 74M | 6.1M | -7.5M |
| Operating Margin | 13.5% | 13.5% | 0.8% | 6.9% | 0.7% | -1.0% |
| ROE | 12.4% | 13.8% | 1.2% | 8.4% | -0.2% | 0.7% |
| Shares Outstanding | 39M | 39M | 39M | 39M | 40M | 38M |
Penumbra Inc passes 5 of 9 quality checks, suggesting mixed fundamentals.
Penumbra Inc trades at 73.3x trailing earnings, compared to its 15-year median P/E of 70.1x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 74.5x vs a median of 67.3x. The company's 5-year average ROIC is 5.4% with a gross margin of 64.3%. At current prices, the estimated annualized return to fair value is +56.6%.
Penumbra Inc (PEN) has a current P/E ratio of 73.3, compared to its historical median P/E of 70.1. The stock is currently considered Expensive based on its historical valuation range.
Penumbra Inc (PEN) has a 5-year average return on invested capital (ROIC) of 5.4%. This is below average and may indicate limited pricing power.
Penumbra Inc (PEN) has a market capitalization of $13.0B. It is classified as a large-cap stock.
Penumbra Inc (PEN) does not currently pay a regular dividend.
Based on historical P/E analysis, Penumbra Inc (PEN) appears expensive. The current P/E of 73.3 is 5% above its historical median of 70.1. The estimated fair value CAGR (P/E method) is 29.3%.
Penumbra Inc (PEN) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Penumbra Inc (PEN) reported annual revenue of $1.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
Penumbra Inc (PEN) has a net profit margin of 12.7%. This is a healthy margin.
Penumbra Inc (PEN) generated $175 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Penumbra Inc (PEN) has a debt-to-equity ratio of 0.15. This indicates a conservatively financed balance sheet.
Penumbra Inc (PEN) reported earnings per share (EPS) of $4.52 in its most recent fiscal year.
Penumbra Inc (PEN) has a return on equity (ROE) of 13.8%. This indicates moderate shareholder returns.
Penumbra Inc (PEN) has a 5-year average gross margin of 64.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for Penumbra Inc (PEN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Penumbra Inc (PEN) has a book value per share of $36.32, based on its most recent annual SEC filing.